Cargando…

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature

The main therapeutic strategy for metastatic Myxofibrosarcoma (MFS) is palliative chemotherapy. A number of studies have demonstrated that anti-angiogenic therapy and immunotherapy could improve the survival rate of patients with metastases. However, the effectiveness of the combination of anti-angi...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Lei, Pan, Dejian, Zhou, Rengui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468213/
https://www.ncbi.nlm.nih.gov/pubmed/32905214
http://dx.doi.org/10.3892/mco.2020.2124
_version_ 1783578170936524800
author Song, Lei
Pan, Dejian
Zhou, Rengui
author_facet Song, Lei
Pan, Dejian
Zhou, Rengui
author_sort Song, Lei
collection PubMed
description The main therapeutic strategy for metastatic Myxofibrosarcoma (MFS) is palliative chemotherapy. A number of studies have demonstrated that anti-angiogenic therapy and immunotherapy could improve the survival rate of patients with metastases. However, the effectiveness of the combination of anti-angiogenic therapy and immunotherapy for the therapy of MFS is undetermined. The current study reports a case of metastatic myxofibrosarcoma that was treated with combination Nivolumab (monoclonal antibody, PD-1 inhibitor) and Bevacizumab (monoclonal antibody, anti-VEGF) after progression from the single use of Nivolumab. The aim of the current study is to assess the efficacy and safety of Nivolumab and Bevacizumab for metastatic myxofibrosarcoma and to review the literature. Up to the termination of the follow-up, the patient achieved a partial response for 16 months, had an overall survival for over 29 months since the metastasis and demonstrated a sustained benefit from treatment. The most frequent adverse events were fatigue, abnormality of Alanine aminotransferase (ALT), hypertension and proteinuria. Nivolumab and Bevacizumab treatment indicate beneficial clinical effects and are indicated to be safe to use in patients with metastatic myxofibrosarcoma.
format Online
Article
Text
id pubmed-7468213
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-74682132020-09-03 Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature Song, Lei Pan, Dejian Zhou, Rengui Mol Clin Oncol Articles The main therapeutic strategy for metastatic Myxofibrosarcoma (MFS) is palliative chemotherapy. A number of studies have demonstrated that anti-angiogenic therapy and immunotherapy could improve the survival rate of patients with metastases. However, the effectiveness of the combination of anti-angiogenic therapy and immunotherapy for the therapy of MFS is undetermined. The current study reports a case of metastatic myxofibrosarcoma that was treated with combination Nivolumab (monoclonal antibody, PD-1 inhibitor) and Bevacizumab (monoclonal antibody, anti-VEGF) after progression from the single use of Nivolumab. The aim of the current study is to assess the efficacy and safety of Nivolumab and Bevacizumab for metastatic myxofibrosarcoma and to review the literature. Up to the termination of the follow-up, the patient achieved a partial response for 16 months, had an overall survival for over 29 months since the metastasis and demonstrated a sustained benefit from treatment. The most frequent adverse events were fatigue, abnormality of Alanine aminotransferase (ALT), hypertension and proteinuria. Nivolumab and Bevacizumab treatment indicate beneficial clinical effects and are indicated to be safe to use in patients with metastatic myxofibrosarcoma. D.A. Spandidos 2020-11 2020-08-24 /pmc/articles/PMC7468213/ /pubmed/32905214 http://dx.doi.org/10.3892/mco.2020.2124 Text en Copyright: © Song et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Song, Lei
Pan, Dejian
Zhou, Rengui
Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
title Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
title_full Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
title_fullStr Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
title_full_unstemmed Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
title_short Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
title_sort combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: a case report and review of the literature
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468213/
https://www.ncbi.nlm.nih.gov/pubmed/32905214
http://dx.doi.org/10.3892/mco.2020.2124
work_keys_str_mv AT songlei combinationnivolumabandbevacizumabformetastaticmyxofibrosarcomaacasereportandreviewoftheliterature
AT pandejian combinationnivolumabandbevacizumabformetastaticmyxofibrosarcomaacasereportandreviewoftheliterature
AT zhourengui combinationnivolumabandbevacizumabformetastaticmyxofibrosarcomaacasereportandreviewoftheliterature